Aerovate Therapeutics (NASDAQ:JBIO) Upgraded by Guggenheim to Buy Rating

Guggenheim upgraded shares of Aerovate Therapeutics (NASDAQ:JBIO – Free Report) from a neutral rating to a buy rating in a research report released on Monday, MarketBeat.com reports. The firm currently has $14.00 price target on the stock. Separately, Wall St…

Read Full Article →